(R)-tert-butyl (1-aminobutan-2-yl)carbamate | 956125-05-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (R)-tert-butyl (1-aminobutan-2-yl)carbamate
• 英文别名: ((R)-1-aminomethyl-propyl)-carbamic acid tert-butyl ester；N-Boc-[(1R)-1-(aminomethyl)propyl]amine；tert-butyl N-[(2R)-1-aminobutan-2-yl]carbamate
• CAS: 956125-05-6
• 化学式: C₉H₂₀N₂O₂
• 分子量: 188.27
• InChiKey: KGJCYTMWAXWVOM-SSDOTTSWSA-N

物化性质

• 沸点：
  281.2±23.0 °C(Predicted)
• 密度：
  0.972±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (R)-tert-butyl (1-aminobutan-2-yl)carbamate 、 3,5-二氨基-6-氯吡嗪-2-羧酸 在 N-甲基吗啉 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 tert-butyl (R)-(1-(3,5-diamino-6-chloropyrazine-2-carboxamido)butan-2-yl)carbamate
  参考文献：
  名称：

  Discovery of a novel chemotype of potent human ENaC blockers using a bioisostere approach. Part 2: α-Branched quaternary amines

  摘要：

  We report the synthesis and biological evaluation of a series of novel alpha-branched pyrazinoyl quaternary amines for their ability to block ion transport via the epithelial sodium channel (ENaC) in human bronchial epithelial cells (HBECs). Compound 12g has an IC50 of 30 nM and is highly efficacious in the Guinea-pig tracheal potential difference (TPD) model of ENaC blockade with an ED50 of 1 mu g kg(-1) at 1 h. In addition the SAR results demonstrate for the first time the chiral nature of the binding site of human ENaC. As such, pyrazinoyl quaternary amines represent a promising new class of ENaC blockers for the treatment of cystic fibrosis that are structurally distinct from the pyrazinoyl guanidine chemotype found in prototypical ENaC blockers such as amiloride. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.02.067
• 作为产物：
  描述：

  N-Boc-(R)-(+)-2-氨基-1-丁醇 在 一水合肼 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 (R)-tert-butyl (1-aminobutan-2-yl)carbamate
  参考文献：
  名称：

  具有手性烷基化咪唑烷环的吡虫啉衍生物的合成及其杀虫活性和对烟碱乙酰胆碱受体的亲和性评估

  摘要：

  不对称合成了一系列具有烷基化咪唑烷环的吡虫啉（IMI）衍生物，以评估其对成年雌性家蝇Musca domestica的杀虫活性以及对果蝇的烟碱乙酰胆碱受体的亲和力。烷基越大，受体亲和力越低，但是在咪唑烷环的R -5-位甲基化和乙基化的衍生物与未取代的化合物等价。受体亲和力的定量结构-活性关系（QSAR）分析表明，将取代基引入咪唑烷环基本上是不利的，但在R处引入取代基如果尺寸较小，则允许-5-位置。合成衍生物与受体的结合模型支持QSAR分析，表明在配体结合位点R -5-位置周围的短烷基存在空间。此外，在杀虫活性和受体亲和力之间观察到正相关，这表明即使修饰了咪唑烷环，受体亲和力也是影响杀虫活性的主要因素。

  DOI：

  10.1016/j.bmc.2012.09.007

文献信息

• Synthesis of imidacloprid derivatives with a chiral alkylated imidazolidine ring and evaluation of their insecticidal activity and affinity to the nicotinic acetylcholine receptor
  作者：Hisashi Nishiwaki、Mituhiro Kuriyama、Hikaru Nagaoka、Akira Kato、Miki Akamatsu、Satoshi Yamauchi、Yoshihiro Shuto

  DOI：10.1016/j.bmc.2012.09.007

  日期：2012.11

  imidazolidine ring were asymmetrically synthesized to evaluate their insecticidal activity against adult female housefly, Musca domestica, and affinity to the nicotinic acetylcholine receptor of the flies. The bulkier the alkyl group, the lower was the receptor affinity, but the derivatives methylated and ethylated at the R-5-position of the imidazolidine ring were equipotent to the unsubstituted compound. Quantitative

  不对称合成了一系列具有烷基化咪唑烷环的吡虫啉（IMI）衍生物，以评估其对成年雌性家蝇Musca domestica的杀虫活性以及对果蝇的烟碱乙酰胆碱受体的亲和力。烷基越大，受体亲和力越低，但是在咪唑烷环的R -5-位甲基化和乙基化的衍生物与未取代的化合物等价。受体亲和力的定量结构-活性关系（QSAR）分析表明，将取代基引入咪唑烷环基本上是不利的，但在R处引入取代基如果尺寸较小，则允许-5-位置。合成衍生物与受体的结合模型支持QSAR分析，表明在配体结合位点R -5-位置周围的短烷基存在空间。此外，在杀虫活性和受体亲和力之间观察到正相关，这表明即使修饰了咪唑烷环，受体亲和力也是影响杀虫活性的主要因素。
• AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE
  申请人：Raynham Tony Michael

  公开号：US20090247519A1

  公开（公告）日：2009-10-01

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain amino-ethyl-amino-aryl (AEAA) compounds which, inter alia, inhibit protein kinase D (PKD) (e.g., PKD1, PKD2, PKD3). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PKD, and in the treatment of diseases and conditions that are mediated by PKD, that are ameliorated by the inhibition of PKD, etc., including proliferative conditions such as cancer, etc.

  本发明一般涉及治疗化合物领域，更具体地涉及某些氨基乙基氨基芳基（AEAA）化合物，该化合物在抑制蛋白激酶D（PKD）（例如，PKD1、PKD2、PKD3）方面起作用。本发明还涉及包含这些化合物的药物组合物，以及在体外和体内使用这些化合物和组合物来抑制PKD，并用于治疗由PKD介导的疾病和症状，通过抑制PKD而改善的疾病和症状等，包括增殖性疾病如癌症等。
• [EN] THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C<br/>[FR] INHIBITEURS DE TYPE THIÉNOPYRIMIDINE DE PROTÉINES KINASES C ATYPIQUES
  申请人：CANCER REC TECH LTD

  公开号：WO2013078126A1

  公开（公告）日：2013-05-30

  The present invention provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have a PKC inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供了一种式（I）的化合物或其盐，其中R1、R2、R3、R4、R5、R6、A、G、M、Q和X如本文所定义。式（I）的化合物及其盐具有PKC抑制活性，并可用于治疗增生性疾病。
• Organic Comopunds
  申请人：Collingwood Stephen Paul

  公开号：US20110201625A1

  公开（公告）日：2011-08-18

  A compound of Formula I or a hydrate or solvate thereof, where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  化合物I的配方或其水合物或溶剂化物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9和R10的含义如规范中所示，可用于治疗对上皮钠通道阻滞有反应的疾病。还描述了含有该化合物的制药组合物和制备该化合物的过程。
• Thienopyrimidine Inhibitors of Atypical Protein Kinase C
  申请人：Cancer Research Technology Limited

  公开号：US20140323435A1

  公开（公告）日：2014-10-30

  The present application provides a compound of formula (I) or a salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.

  本申请提供了公式（I）的化合物或其盐，其中R1、R2、R3、R4、R5、R6、A、G、M、Q和X的定义如本文所述。公式（I）的化合物及其盐具有aPKC抑制活性，可用于治疗增殖性疾病。